Literature DB >> 25060102

Melatonin: a well-documented antioxidant with conditional pro-oxidant actions.

Hong-Mei Zhang1, Yiqiang Zhang.   

Abstract

Melatonin (N-acetyl-5-methoxytryptamine), an indoleamine produced in many organs including the pineal gland, was initially characterized as a hormone primarily involved in circadian regulation of physiological and neuroendocrine function. Subsequent studies found that melatonin and its metabolic derivatives possess strong free radical scavenging properties. These metabolites are potent antioxidants against both ROS (reactive oxygen species) and RNS (reactive nitrogen species). The mechanisms by which melatonin and its metabolites protect against free radicals and oxidative stress include direct scavenging of radicals and radical products, induction of the expression of antioxidant enzymes, reduction of the activation of pro-oxidant enzymes, and maintenance of mitochondrial homeostasis. In both in vitro and in vivo studies, melatonin has been shown to reduce oxidative damage to lipids, proteins and DNA under a very wide set of conditions where toxic derivatives of oxygen are known to be produced. Although the vast majority of studies proved the antioxidant capacity of melatonin and its derivatives, a few studies using cultured cells found that melatonin promoted the generation of ROS at pharmacological concentrations (μm to mm range) in several tumor and nontumor cells; thus, melatonin functioned as a conditional pro-oxidant. Mechanistically, melatonin may stimulate ROS production through its interaction with calmodulin. Also, melatonin may interact with mitochondrial complex III or mitochondrial transition pore to promote ROS production. Whether melatonin functions as a pro-oxidant under in vivo conditions is not well documented; thus, whether the reported in vitro pro-oxidant actions come into play in live organisms remains to be established.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antioxidant; free radicals; melatonin; mitochondria; pro-oxidant; reactive nitrogen species; reactive oxygen species

Mesh:

Substances:

Year:  2014        PMID: 25060102     DOI: 10.1111/jpi.12162

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  169 in total

1.  Evaluation of melatonin and AFMK levels in women with breast cancer.

Authors:  Tialfi Bergamin de Castro; Newton Antônio Bordin-Junior; Eduardo Alves de Almeida; Debora Aparecida Pires de Campos Zuccari
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

2.  Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.

Authors:  L Zhou; X Chen; J Yan; M Li; T Liu; C Zhu; G Pan; Q Guo; H Yang; M Pei; F He
Journal:  Osteoporos Int       Date:  2017-09-27       Impact factor: 4.507

3.  Melatonin reverses H2 O2 -induced premature senescence in mesenchymal stem cells via the SIRT1-dependent pathway.

Authors:  Long Zhou; Xi Chen; Tao Liu; Yihong Gong; Sijin Chen; Guoqing Pan; Wenguo Cui; Zong-Ping Luo; Ming Pei; Huilin Yang; Fan He
Journal:  J Pineal Res       Date:  2015-07-07       Impact factor: 13.007

4.  Melatonin Delivery: Transdermal and Transbuccal Evaluation in Different Vehicles.

Authors:  Ana Flo; Ana C Calpena; Lyda Halbaut; Erika I Araya; Francisco Fernández; Beatriz Clares
Journal:  Pharm Res       Date:  2016-03-08       Impact factor: 4.200

5.  Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.

Authors:  Néstor Prieto-Domínguez; Raquel Ordóñez; Anna Fernández; Carolina Méndez-Blanco; Anna Baulies; Carmen Garcia-Ruiz; José C Fernández-Checa; José L Mauriz; Javier González-Gallego
Journal:  J Pineal Res       Date:  2016-08-19       Impact factor: 13.007

6.  Melatonin-pretreated adipose-derived mesenchymal stem cells efficeintly improved learning, memory, and cognition in an animal model of Alzheimer's disease.

Authors:  Ebrahim Nasiri; Akram Alizadeh; Amaneh Mohammadi Roushandeh; Rouhollah Gazor; Nasrin Hashemi-Firouzi; Zoleikha Golipoor
Journal:  Metab Brain Dis       Date:  2019-05-25       Impact factor: 3.584

7.  Melatonin Improves Memory Deficits in Rats with Cerebral Hypoperfusion, Possibly, Through Decreasing the Expression of Small-Conductance Ca2+-Activated K+ Channels.

Authors:  Hussain Al Dera; Mohammed Alassiri; Samy M Eleawa; Mahmoud A AlKhateeb; Abdelaziz M Hussein; Mohammad Dallak; Hussein F Sakr; Sultan Alqahtani; Mohammad A Khalil
Journal:  Neurochem Res       Date:  2019-06-11       Impact factor: 3.996

8.  Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release.

Authors:  Yalikun Suofu; Wei Li; Frédéric G Jean-Alphonse; Jiaoying Jia; Nicolas K Khattar; Jiatong Li; Sergei V Baranov; Daniela Leronni; Amanda C Mihalik; Yanqing He; Erika Cecon; Vanessa L Wehbi; JinHo Kim; Brianna E Heath; Oxana V Baranova; Xiaomin Wang; Matthew J Gable; Eric S Kretz; Giulietta Di Benedetto; Timothy R Lezon; Lisa M Ferrando; Timothy M Larkin; Mara Sullivan; Svitlana Yablonska; Jingjing Wang; M Beth Minnigh; Gérald Guillaumet; Franck Suzenet; R Mark Richardson; Samuel M Poloyac; Donna B Stolz; Ralf Jockers; Paula A Witt-Enderby; Diane L Carlisle; Jean-Pierre Vilardaga; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

Review 9.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

10.  Melatonin receptor signaling contributes to neuroprotection upon arousal from torpor in thirteen-lined ground squirrels.

Authors:  Christine Schwartz; Mallory A Ballinger; Matthew T Andrews
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-09-09       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.